Preclinical study demonstrates the assembly and pharmacological activity of a modular antibody platform, highlighting a universal mix-and-match approach for cancer immunotherapy discovery.
assembly and subsequent pharmacological activity, and provide preclinical proof-of-concept for the P329G-engager platform as an efficacious tool in drug discovery. Ultimately, this modular approach may enable mix-and-match drug assembly as a novel therapeutic principle in immunotherapy.
No takes yet. Share an insight, caveat, or question.
Surowka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: